TrialsgrambetaRCTs are beautiful

Interstitial lung disease & IPF

Antifibrotics in IPF, progressive fibrosing ILD and SSc-ILD; refutation of immunosuppression for IPF.

Trials
5
Years
2012–2019
Sort
  • 2019INBUILD⁠Progressive fibrosing ILDIn 663 patients with non-IPF progressive fibrosing ILD, nintedanib slowed annual FVC decline compared with placebo.Read →
  • 2019SENSCIS⁠SSc-ILDIn 576 patients with SSc-associated ILD, nintedanib slowed annual FVC decline compared with placebo.Read →
  • 2014INPULSIS Core⁠Antifibrotic: IPFIn 1,066 patients with idiopathic pulmonary fibrosis, nintedanib 150 mg twice daily slowed annual FVC decline compared with placebo.Read →
  • 2014ASCEND Core⁠Antifibrotic: IPFIn 555 patients with IPF (FVC 50–90% predicted), pirfenidone 2,403 mg/day reduced ≥10% FVC decline or death at 52 weeks compared with placebo.16.5% vs 31.8%Read →
  • 2012PANTHER-IPF Core⁠Immunosuppression: IPFIn patients with idiopathic pulmonary fibrosis, prednisone + azathioprine + NAC increased mortality and hospitalisation compared with placebo.HR 12.1195% CI 2.83-51.85Read →